Status of Institutional Review Board Meetings Conducted Through Web Conference Systems in Japanese National University Hospitals During the COVID-19 Pandemic: Questionnaire Study.


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
19 11 2020
Historique:
received: 08 07 2020
accepted: 26 10 2020
revised: 06 08 2020
pubmed: 29 10 2020
medline: 27 11 2020
entrez: 28 10 2020
Statut: epublish

Résumé

With the global proliferation of the novel COVID-19 disease, conventionally conducting institutional review board (IRB) meetings has become a difficult task. Amid concerns about the suspension of drug development due to delays within IRBs, it has been suggested that IRB meetings should be temporarily conducted via the internet. This study aimed to elucidate the current status of IRB meetings conducted through web conference systems. A survey on conducting IRB meetings through web conference systems was administered to Japanese national university hospitals. Respondents were in charge of operating IRB offices at different universities. This study was not a randomized controlled trial. The survey was performed at 42 facilities between the end of May and early June, 2020, immediately after the state of emergency was lifted in Japan. The survey yielded a response rate of 74% (31/42). Additionally, while 68% (21/31) of facilities introduced web conference systems for IRB meetings, 13% (4/31) of the surveyed facilities postponed IRB meetings. Therefore, we conducted a further survey of 21 facilities that implemented web conference systems for IRB meetings. According to 71% (15/21) of the respondents, there was no financial burden for implementing these systems, as they were free of charge. In 90% (19/21) of the facilities, IRB meetings through web conference systems were already being conducted with personal electronic devices. Furthermore, in 48% (10/21) of facilities, a web conference system was used in conjunction with face-to-face meetings. Due to the COVID-19 pandemic, the number of reviews in clinical trial core hospitals has decreased. This suggests that the development of pharmaceuticals has stagnated because of COVID-19. According to 71% (15/21) of the respondents who conducted IRB meetings through web conference systems, the cost of introducing such meetings was US $0, showing a negligible financial burden. Moreover, it was shown that online deliberations could be carried out in the same manner as face-to-face meetings, as 86% (18/21) of facilities stated that the number of comments made by board members did not change. To improve the quality of IRB meetings conducted through web conference systems, it is necessary to further examine camera use and the content displayed on members' screens during meetings. Further examination of all members who use web conference systems is required. Our measures for addressing the requests and problems identified in our study could potentially be considered protocols for future IRB meetings, when the COVID-19 pandemic has passed and face-to-face meetings are possible again. This study also highlights the importance of developing web conference systems for IRB meetings to respond to future unforeseen pandemics.

Sections du résumé

BACKGROUND
With the global proliferation of the novel COVID-19 disease, conventionally conducting institutional review board (IRB) meetings has become a difficult task. Amid concerns about the suspension of drug development due to delays within IRBs, it has been suggested that IRB meetings should be temporarily conducted via the internet.
OBJECTIVE
This study aimed to elucidate the current status of IRB meetings conducted through web conference systems.
METHODS
A survey on conducting IRB meetings through web conference systems was administered to Japanese national university hospitals. Respondents were in charge of operating IRB offices at different universities. This study was not a randomized controlled trial.
RESULTS
The survey was performed at 42 facilities between the end of May and early June, 2020, immediately after the state of emergency was lifted in Japan. The survey yielded a response rate of 74% (31/42). Additionally, while 68% (21/31) of facilities introduced web conference systems for IRB meetings, 13% (4/31) of the surveyed facilities postponed IRB meetings. Therefore, we conducted a further survey of 21 facilities that implemented web conference systems for IRB meetings. According to 71% (15/21) of the respondents, there was no financial burden for implementing these systems, as they were free of charge. In 90% (19/21) of the facilities, IRB meetings through web conference systems were already being conducted with personal electronic devices. Furthermore, in 48% (10/21) of facilities, a web conference system was used in conjunction with face-to-face meetings.
CONCLUSIONS
Due to the COVID-19 pandemic, the number of reviews in clinical trial core hospitals has decreased. This suggests that the development of pharmaceuticals has stagnated because of COVID-19. According to 71% (15/21) of the respondents who conducted IRB meetings through web conference systems, the cost of introducing such meetings was US $0, showing a negligible financial burden. Moreover, it was shown that online deliberations could be carried out in the same manner as face-to-face meetings, as 86% (18/21) of facilities stated that the number of comments made by board members did not change. To improve the quality of IRB meetings conducted through web conference systems, it is necessary to further examine camera use and the content displayed on members' screens during meetings. Further examination of all members who use web conference systems is required. Our measures for addressing the requests and problems identified in our study could potentially be considered protocols for future IRB meetings, when the COVID-19 pandemic has passed and face-to-face meetings are possible again. This study also highlights the importance of developing web conference systems for IRB meetings to respond to future unforeseen pandemics.

Identifiants

pubmed: 33112758
pii: v22i11e22302
doi: 10.2196/22302
pmc: PMC7683025
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e22302

Informations de copyright

©Kenta Yagi, Kazuki Maeda, Satoshi Sakaguchi, Masayuki Chuma, Yasutaka Sato, Chikako Kane, Akiyo Akaishi, Keisuke Ishizawa, Hiroaki Yanagawa. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 19.11.2020.

Références

J Med Internet Res. 2020 Jun 25;22(6):e19771
pubmed: 32519964
J Med Internet Res. 2020 Jun 15;22(6):e17417
pubmed: 32459637
Lancet. 2020 Mar 28;395(10229):1015-1018
pubmed: 32197103
Learn Health Syst. 2018 Dec 03;3(1):e10073
pubmed: 31245596
J Med Internet Res. 2020 Jun 16;22(6):e18203
pubmed: 32543441
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
J Med Internet Res. 2017 Mar 24;19(3):e90
pubmed: 28341617
Eur Urol. 2020 Sep;78(3):301-303
pubmed: 32334884
J Med Internet Res. 2004 Sep 29;6(3):e34
pubmed: 15471760
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
J Med Internet Res. 2020 Jul 6;22(7):e19322
pubmed: 32568721

Auteurs

Kenta Yagi (K)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Kazuki Maeda (K)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Satoshi Sakaguchi (S)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Masayuki Chuma (M)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Yasutaka Sato (Y)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Chikako Kane (C)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Akiyo Akaishi (A)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Keisuke Ishizawa (K)

Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Kuramoto-cho, Tokushima, Japan.
Department of Pharmacy, Tokushima University Hospital, Kuramoto-cho, Tokushima, Japan.

Hiroaki Yanagawa (H)

Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH